Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
Actuate 1801. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies
Sponsored by Actuate Therapeutics, Inc.
Active
$432.5K Funding
7 People
External
Related Topics
gsk-3b inhibitor,
hematologic malignancies,
chemotherapy
People
Bryan Clines
(CD)
Cancer Center Division
﹒Research Compliance Administrator III
Brianna Loughran
(CD)
Cancer Center Division
﹒Clinical Research Coordinator II
Junaid Arshad
Co-Investigator (COI)
Medicine
﹒Assistant Professor, Medicine - (Clinical Scholar Track)
Hina Arif Tiwari
Co-Investigator (COI)
Pathology
﹒Professor
Brianna Denton
(CD)
Cancer Center Division
﹒Research Compliance Manager I
Diana Dawson
(CD)
Cancer Center Division
﹒Research Compliance Administrator II
Rachna Shroff
Principal Investigator (PI)
Medicine
﹒Professor